Asset Details
Do you wish to reserve the book?
Oral oncolytic magnetotactic bacteria elicit anti-colorectal tumor immunity and reprogram microbiota metabolism
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Oral oncolytic magnetotactic bacteria elicit anti-colorectal tumor immunity and reprogram microbiota metabolism
Do you wish to request the book?
Oral oncolytic magnetotactic bacteria elicit anti-colorectal tumor immunity and reprogram microbiota metabolism
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Oral oncolytic magnetotactic bacteria elicit anti-colorectal tumor immunity and reprogram microbiota metabolism
2025
Overview
Therapeutic outcomes of colorectal cancer (CRC) are influenced by intestinal microbiota and metabolites. To leverage the tumor-tropism and microbiota-regulating properties of bacteria, we developed oncolytic magnetotactic bacteria (MSR-CPT/APPs) loaded with camptothecin (CPT) and anti-PD-L1 peptide (APP) for targeted chemo-magnetothermal immunotherapy of CRC. To further achieve oral delivery, MSR-CPT/APPs were coated with mulberry leaf lipids and Pluronic F127 (LPs). When exposed to an alternating magnetic field, MSR-CPT/APP@LPs penetrated colonic mucus and reached deep-seated tumors. They elevated proinflammatory cytokine secretion, prolonged T cell recruitment, and reduced immunosuppressive cell proportions by activating the cGAS-STING pathway, inducing immunogenic cell death, and facilitating macrophage polarization to M1 phenotype. Oral MSR-CPT/APP@LPs increased the relative abundances of crucial commensal microorganisms (e.g., Lachnospiraceae family and Alistipes) and influenced their metabolites, like elevating beneficial metabolites (short-chain fatty acids and citrulline) levels and decreasing harmful metabolites (l-glutamine and kynurenic acid) amounts, thereby remodeling the tumor immune microenvironment. Overall, MSR-CPT/APP@LPs foster a supportive intestinal environment and mitigate immunosuppression, achieving the eradication of both primary and distant colorectal tumors.
TOC 1. After oral administration, MSR-CPT/APP@LP magnetic motors achieve stable gastrointestinal transit, accumulate in the tumor tissues, and modulate the metabolic program of intestinal microflora. [Display omitted]
•Oncolytic magnetotactic bacteria for targeted CRC therapy was constructed.•Protective shells and AMF exposure allow oral bacteria to safely reach deep tumors.•MSR-CPT/APP@LPs plus AMF exposure elicit innate and adaptive immune immunity.•MSR-CPT/APP@LPs plus AMF exposure greatly reprogram gut microbiota and metabolites.•MSR-CPT/APP@LPs plus AMF exposure foster an immune-supportive microenvironment.
